Test combo treatment for cancers with DNA repair gene mutations
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to sign consent and follow the visit schedule
- Have an advanced solid tumor (not prostate) that can be treated with a topoisomerase I inhibitor and has a DNA repair gene defect like BRCA1, BRCA2, ATM, or PALB2
- Have at least one measurable tumor spot on scans and no curative treatment option
- Finish prior cancer therapy and be recovered enough (including acceptable blood counts and organ test results) before starting
- Be able to take pills by mouth and have adequate kidney, liver, blood, and overall health status
- Use strict birth control during treatment and for months after (or you must not be able to get pregnant / not be able to father a child)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This trial tests a drug that may help people with advanced breast cancer who have a specific genetic change (in the PALB2 gene). The drug is a PARP inhibitor, which works by targeting cancer cells that have trouble repairing their DNA.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.